标题
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume 167, Issue 1, Pages 19-32
出版商
Wiley
发表日期
2014-08-06
DOI
10.1111/bjh.13065
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Making new contacts: the mTOR network in metabolism and signalling crosstalk
- (2014) Mitsugu Shimobayashi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
- (2014) Alberto Ocana et al. PLoS One
- Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma
- (2014) M A Dengler et al. Cell Death & Disease
- P110 -mediated constitutive PI3K signaling limits the efficacy of p110 -selective inhibition in mantle cell lymphoma, particularly with multiple relapse
- (2013) S. Iyengar et al. BLOOD
- Comprehensive analysis of PTEN status in Sezary syndrome
- (2013) C. Cristofoletti et al. BLOOD
- The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways
- (2013) Juraj Bodo et al. BRITISH JOURNAL OF HAEMATOLOGY
- PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
- (2013) K. Walsh et al. CLINICAL CANCER RESEARCH
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency
- (2013) Carrie L Lucas et al. NATURE IMMUNOLOGY
- Memory of Conditioned Taste Aversion Is Erased by Inhibition of PI3K in the Insular Cortex
- (2013) Ilana Slouzkey et al. NEUROPSYCHOPHARMACOLOGY
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoinositide 3-Kinase Gene Mutation Predisposes to Respiratory Infection and Airway Damage
- (2013) I. Angulo et al. SCIENCE
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
- (2012) Rosa Lapalombella et al. CANCER CELL
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen
- (2012) Haitao Bai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia
- (2012) Zhi-Jian Zou et al. LEUKEMIA & LYMPHOMA
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- (2012) Areumnuri Kim et al. LEUKEMIA RESEARCH
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
- (2012) Kevin A. Kwei et al. PLoS One
- The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival
- (2011) Antònia Obrador-Hevia et al. BRITISH JOURNAL OF HAEMATOLOGY
- Akt signalling in health and disease
- (2011) Ingeborg Hers et al. CELLULAR SIGNALLING
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- (2011) Stephen M Ansell et al. LANCET ONCOLOGY
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome
- (2011) Marjorie J. Lindhurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
- (2010) Sonali M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation
- (2010) Sandra Beer-Hammer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Phosphatidylinositol 3'-Kinase Catalytic Subunit Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
- (2009) A. Psyrri et al. CLINICAL CANCER RESEARCH
- PTEN hamartoma tumor syndrome: An overview
- (2009) Judith A Hobert et al. GENETICS IN MEDICINE
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources
- (2009) Chunlei Wu et al. GENOME BIOLOGY
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
- (2008) J. Dal Col et al. BLOOD
- Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85α subunit of phosphoinositide-3 kinase
- (2008) Chihiro Tohda et al. BRAIN & DEVELOPMENT
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started